Summary
A research-focused overview of peptides studied for cognitive performance, neuroprotection, anxiety reduction, and neuroplasticity — covering Semax, Selank, Dihexa, and Pinealon.
The Cognitive Performance Problem
Cognitive performance operates across multiple independent systems:
- Working memory and executive function — frontal-parietal circuits, dopamine-dependent
- Long-term memory consolidation — hippocampal neurogenesis and synaptic plasticity, BDNF-dependent
- Attention and processing speed — norepinephrine, acetylcholine, and catecholamine-dependent
- Emotional regulation and stress resilience — amygdala-prefrontal circuits, GABAergic and serotonergic
- Neuroprotection and cognitive reserve — antioxidant capacity, mitochondrial function, anti-apoptotic signalling
Most pharmaceutical cognitive enhancers target a single neurotransmitter system. Peptide-based research often takes a different approach — acting through neurotrophic factors (BDNF, NGF, HGF) or neuroprotective pathways that operate upstream of specific neurotransmitter deficits.
Semax: BDNF Upregulation and Neuroprotection
Semax is among the few nootropic peptides with documented clinical approval. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it is registered in Russia and Ukraine for:
- Ischaemic stroke (acute phase)
- Optic nerve disease
- Cognitive decline and attention disorders
- Peptic ulcer disease (via CNS-gut axis modulation)
Structure and mechanism:
Semax is a heptapeptide analogue of the ACTH(4-7) sequence: Met-Glu-His-Phe-Pro-Gly-Pro. The ACTH sequence itself promotes alertness and cognitive function; Semax is specifically designed to be stable, non-hormonal, and neurologically active without the adrenocortical effects of full ACTH.
Primary mechanisms:
-
BDNF upregulation: Semax consistently increases BDNF expression in the hippocampus and cortex in animal models — the clearest mechanistic rationale for its cognitive effects. BDNF drives long-term potentiation (LTP), the cellular mechanism of memory formation.
-
Dopaminergic modulation: Semax increases dopamine turnover in the nucleus accumbens and frontal cortex, relevant to motivation, attention, and working memory.
-
Neuroprotection: In stroke and ischaemia models, Semax reduces the area of neuronal death, suppresses oxidative stress, and preserves tissue in the penumbral zone (the salvageable brain tissue surrounding the infarct core).
-
Cognitive enhancement in healthy models: Rodent studies show improved maze learning, reduced forgetting rates, and enhanced attention in non-injured subjects — suggesting the compound has direct cognitive effects beyond pure neuroprotection.
Nasal spray delivery:
Semax is administered intranasally because the olfactory epithelium provides direct anatomical access to the central nervous system via the olfactory nerve, bypassing the blood-brain barrier. This route achieves CNS concentrations substantially higher than equivalent systemic administration.
Selank: Anxiolytic Neuropeptide with Cognitive Effects
Selank is a synthetic analogue of tuftsin (Thr-Lys-Pro-Arg) with added amino acids to improve stability. Tuftsin is an endogenous tetrapeptide produced from IgG that has immunomodulatory and nootropic properties.
Selank was developed at the Institute of Molecular Genetics alongside Semax and is clinically approved in Russia as an anxiolytic and nootropic.
Primary mechanisms:
-
GABAergic modulation: Selank positively modulates GABA-A receptor function — the same receptor class targeted by benzodiazepines — but without sedation, dependence risk, or receptor downregulation.
-
Serotonin system: Increases serotonin turnover in limbic structures, contributing to emotional regulation and stress response reduction.
-
Enkephalin system: Inhibits enkephalinase, increasing endogenous enkephalin levels — which modulate fear, anxiety, and emotional memory.
-
BDNF/NGF expression: Like Semax, Selank has been observed to increase neurotrophic factor expression — creating cognitive benefits that compound its anxiolytic effects.
Cognitive-anxiolytic profile:
The combination of anxiety reduction and BDNF upregulation is particularly relevant for cognitive performance. Chronic anxiety impairs hippocampal neurogenesis, long-term potentiation, and working memory — mechanisms directly opposing BDNF's cognitive benefits. Selank addresses both simultaneously.
Selank produces anxiolysis without sedation in animal models and clinical observations — a key distinction from benzodiazepines, which impair memory consolidation.
Dihexa: Synaptogenesis via HGF/Met Potentiation
Dihexa (PNB-0408) is a novel cognitive compound developed at Washington State University specifically through the HGF/Met signalling pathway — a less-explored but potent route to neuroplasticity.
What HGF/Met does in the brain:
HGF (hepatocyte growth factor) and its receptor Met are best known from liver regeneration research, but Met receptor expression is high in hippocampal neurons. HGF/Met signalling drives:
- Dendritic spine density and morphology
- Synaptogenesis — formation of new functional synapses
- Neuronal survival under excitotoxic and ischaemic conditions
- Axonal guidance and circuit formation
Dihexa's discovered property:
In vitro and in vivo testing found Dihexa to be approximately seven orders of magnitude more potent than BDNF at promoting synaptogenesis — a remarkable finding given BDNF is considered the gold standard for neuroplasticity enhancement.
Alzheimer's disease model data:
Dihexa showed cognitive restoration in aged rat models of Alzheimer-like cognitive decline, with improvements in water maze performance comparable to young animals. The proposed mechanism is restoration of functional synaptic density in hippocampal circuits lost to neurodegeneration.
As of 2026, no human clinical trials for Dihexa have been published. Its potency and mechanism are novel; safety data in humans is absent from the published literature.
Pinealon: Neuroprotection via Epigenetic Gene Regulation
Pinealon (Glu-Asp-Arg) is a tripeptide derived from the pineal gland, related to epitalon (which is also pineal-derived). Where epitalon targets telomere biology systemically, pinealon research concentrates on neural tissue protection.
Pinealon research applications:
- Ischaemia and hypoxia: Reduces neuronal apoptosis in brain ischaemia models, preserving tissue in oxygen-deprived conditions.
- Antioxidant capacity: Maintains superoxide dismutase and catalase activity in brain tissue under oxidative stress.
- Epigenetic regulation: Modulates gene expression in neural cells, including genes governing cell cycle regulation and survival — a mechanism shared with other bioregulatory peptides from the same research tradition.
- Age-related neurodegeneration models: Attenuates cognitive decline markers in aged rodent models.
Pinealon is often positioned in longevity-cognition protocols — addressing the neural component of ageing alongside epitalon's systemic telomere effects.
Cognitive Peptide Profiles Compared
| Compound | Primary pathway | Main cognitive benefit | Evidence type |
|---|---|---|---|
| Semax | BDNF, dopamine, neuroprotection | Focus, memory, stroke recovery | Clinical (Russia/Ukraine) + preclinical |
| Selank | GABA-A, serotonin, enkephalins | Anxiety reduction, emotional regulation, memory consolidation | Clinical (Russia) + preclinical |
| Dihexa | HGF/Met, synaptogenesis | Memory formation, neuroplasticity, potential Alzheimer's | Preclinical only |
| Pinealon | Epigenetic, neuroprotection | Ischaemia protection, age-related decline | Preclinical (Russian) |
Delivery Route: Why Nasal Spray Matters for Cognitive Compounds
The blood-brain barrier (BBB) restricts passage of most peptides from blood to brain tissue. Intranasal delivery exploits a direct anatomical route: the olfactory and trigeminal nerve pathways provide a physical connection between the nasal mucosa and the central nervous system.
Comparative studies show intranasal BDNF, insulin, and various peptides achieve 10–100x higher brain tissue concentrations than equivalent IV doses. For Semax and Selank — which are specifically formulated as nasal sprays — intranasal delivery is not an alternative but the primary therapeutic route.
Frequently Asked Questions
Can Semax and Selank be used together?
Yes — the combination is widely studied in Russian clinical practice and by independent researchers. They operate through complementary pathways (BDNF/dopamine vs GABA/serotonin) and are not pharmacologically antagonistic. The rationale is combining pro-cognitive (Semax) with anxiolytic-stabilising (Selank) effects for a comprehensive cognitive enhancement and resilience protocol.
What is the difference between Semax and N-Acetyl Semax?
N-Acetyl Semax adds an acetyl group to the N-terminus, which increases lipophilicity, potentially improving BBB penetration and tissue retention. Some researchers report the N-Acetyl form produces more pronounced and longer-lasting effects at equivalent doses, though direct comparative data is limited.
How does Dihexa compare to racetams or traditional nootropics?
Mechanistically, Dihexa is in a completely different category. Racetams (piracetam, aniracetam) modulate AMPA receptors and acetylcholine systems. Dihexa acts via HGF/Met on the structural formation of synapses themselves — building new connections rather than modulating transmission through existing ones. The potency differential is enormous in vitro, but human translation remains unestablished.
Are cognitive peptides safe for long-term use?
Long-term safety data for Semax and Selank comes primarily from Russian clinical practice spanning several decades, suggesting reasonable safety profiles at therapeutic doses. For Dihexa and Pinealon, long-term human safety data is absent. All cognitive peptides should be approached within a structured research protocol with medical oversight.
Source Research-Grade Cognitive Peptides in Bali
BioPepTech lists Semax, Selank, Dihexa, and Pinealon for research use in Bali. Review product pages for current formats, available batch records, and delivery confirmation.
- Semax Nasal Spray — BDNF-upregulating neuroprotective heptapeptide
- Selank Nasal Spray — GABAergic anxiolytic with cognitive benefits
- Dihexa — HGF/Met potentiator for synaptogenesis research
- Pinealon — Pineal-derived neuroprotective tripeptide
A free expert consultation is included with every order — our research team helps design protocol approaches matched to specific cognitive research objectives.
References
Dolotov OV et al. Semax, an analogue of ACTH, increases BDNF expression in the rat brain. Peptides. 2006;27(12):3273-9.
Seredenin SB et al. Pharmacological effects of Selank. Eksp Klin Farmakol. 2008;71(4):3-11.
Grigorev VV et al. Selank peptide modulates GABA-A receptor activity. Bull Exp Biol Med. 2009.
Matzinger M et al. Dihexa, a novel hepatocyte growth factor/Met system enhancer, improves cognitive function in a rodent model of Alzheimer's disease. Neuropsychopharmacology. 2014.
Khavinson VK et al. Peptide regulation of gene expression and protein synthesis in brain neurons. Neurosci Behav Physiol. 2010.
Research Use Only Disclaimer
BioPepTech products are supplied strictly for research use only. They are not intended for human consumption and are not intended to diagnose, treat, cure, or prevent disease.
Safety & Regulatory Note
Semax and Selank are clinically approved in Russia; their regulatory status varies by country — they are not approved in the EU, UK, or USA for medical use. Dihexa is a research compound with no approved clinical applications. All compounds are for research use only. Cognitive-acting peptides may interact with psychiatric medications; individuals on antidepressants, anxiolytics, or antipsychotics should not use these compounds without medical supervision.
References
- 1.Gudasheva TA et al. The synthesis of a hexapeptide PNB-0408 with nootropic activity. Pharm Chem J. 2014.
- 2.Matzinger M et al. Dihexa, a novel hepatocyte growth factor/Met system enhancer, improves cognitive function. Neuropsychopharmacology. 2014.
- 3.Seredenin SB et al. Pharmacological effects of Selank. Eksp Klin Farmakol. 2008.
- 4.Grigorev VV et al. Selank peptide modulates GABA-A receptor activity. Bull Exp Biol Med. 2009.
- 5.Dolotov OV et al. Semax, an analogue of ACTH, increases BDNF expression in the rat brain. Peptides. 2006.